Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) closed its previously announced upsized underwritten public offering of 21,045,000 shares of common stock at $20.50 per share. This total includes 2,745,000 shares sold upon the underwriters’ full exercise of their option to purchase additional shares.
According to Dyne Therapeutics, the offering generated gross proceeds of approximately $431.4 million before underwriting discounts, commissions and expenses. All shares were issued and sold by the company under an automatically effective Form S-3 shelf registration, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones managing the deal.
Positive
- Gross proceeds of approximately $431.4 million raised before costs
- Underwriters fully exercised option for 2,745,000 additional shares
- All 21,045,000 shares sold were primary, raising capital for the company
Negative
- Equity dilution from issuance of 21,045,000 new common shares
News Explained
The completed company-funded share issuance increases the share count and reduces existing holders’ percentage ownership absent offsetting changes.
Dyne Therapeutics has closed the offering, so the disclosed
“Underwritten” means investment banks bought the securities from the issuer for resale; the Form S-3 provided future selling capacity, while the prospectus supplement stated this takedown’s final terms.
The gross proceeds equal
Sources and calculations
- Dyne Therapeutics offering closing release (2026-07-23)
- Dilution definition (undated)
- Underwritten offering definition (undated)
- Form S-3 purpose (undated)
- Prospectus supplement purpose (undated)
- Dyne Therapeutics first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $431,400,000 / ($144,922,000 / 90) = [object Object]
News Market Reaction – DYN
In the Jul 24 session, DYN gained 2.30%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Offering pricing | Negative | -2.6% | Upsized common-stock offering priced at $20.50 per share |
| Jul 21 | Proposed offering | Negative | -2.6% | Company commenced a $300 million common-stock offering |
| Dec 11 | Offering closing | Negative | -0.8% | Company closed a $402.5 million upsized stock offering |
| Dec 9 | Offering pricing | Negative | +6.8% | Upsized $350 million offering priced at $18.44 per share |
| Dec 8 | Proposed offering | Negative | -16.9% | Company commenced a $300 million common-stock offering |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific offering events produced negative 24-hour reactions in four of five cases, with one positive divergence.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of
Morgan Stanley, Jefferies and Evercore ISI acted as joint book-running managers for the offering. LifeSci Capital and Raymond James also acted as joint book-running managers for the offering. Jones acted as lead manager for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
